2.50
Hdl Handle:
http://hdl.handle.net/2436/620315
Title:
The epigenetic landscape of renal cancer.
Authors:
Morris, Mark R; Latif, Farida
Abstract:
The majority of kidney cancers are associated with mutations in the von Hippel-Lindau gene and a small proportion are associated with infrequent mutations in other well characterized tumour-suppressor genes. In the past 15 years, efforts to uncover other key genes involved in renal cancer have identified many genes that are dysregulated or silenced via epigenetic mechanisms, mainly through methylation of promoter CpG islands or dysregulation of specific microRNAs. In addition, the advent of next-generation sequencing has led to the identification of several novel genes that are mutated in renal cancer, such as PBRM1, BAP1 and SETD2, which are all involved in histone modification and nucleosome and chromatin remodelling. In this Review, we discuss how altered DNA methylation, microRNA dysregulation and mutations in histone-modifying enzymes disrupt cellular pathways in renal cancers.
Citation:
The epigenetic landscape of renal cancer. 2017, 13 (1):47-60 Nat Rev Nephrol
Publisher:
Macmillan Publishers Limited, part of Springer Nature
Journal:
Nature reviews. Nephrology
Issue Date:
Jan-2017
URI:
http://hdl.handle.net/2436/620315
DOI:
10.1038/nrneph.2016.168
PubMed ID:
27890923
Additional Links:
http://www.nature.com/nrneph/journal/v13/n1/full/nrneph.2016.168.html
Type:
Article
Language:
en
ISSN:
1759-5061
Appears in Collections:
FSE

Full metadata record

DC FieldValue Language
dc.contributor.authorMorris, Mark Ren
dc.contributor.authorLatif, Faridaen
dc.date.accessioned2016-12-19T15:33:05Z-
dc.date.available2016-12-19T15:33:05Z-
dc.date.issued2017-01-
dc.identifier.citationThe epigenetic landscape of renal cancer. 2017, 13 (1):47-60 Nat Rev Nephrolen
dc.identifier.issn1759-5061en
dc.identifier.pmid27890923-
dc.identifier.doi10.1038/nrneph.2016.168-
dc.identifier.urihttp://hdl.handle.net/2436/620315-
dc.description.abstractThe majority of kidney cancers are associated with mutations in the von Hippel-Lindau gene and a small proportion are associated with infrequent mutations in other well characterized tumour-suppressor genes. In the past 15 years, efforts to uncover other key genes involved in renal cancer have identified many genes that are dysregulated or silenced via epigenetic mechanisms, mainly through methylation of promoter CpG islands or dysregulation of specific microRNAs. In addition, the advent of next-generation sequencing has led to the identification of several novel genes that are mutated in renal cancer, such as PBRM1, BAP1 and SETD2, which are all involved in histone modification and nucleosome and chromatin remodelling. In this Review, we discuss how altered DNA methylation, microRNA dysregulation and mutations in histone-modifying enzymes disrupt cellular pathways in renal cancers.en
dc.language.isoenen
dc.publisherMacmillan Publishers Limited, part of Springer Natureen
dc.relation.urlhttp://www.nature.com/nrneph/journal/v13/n1/full/nrneph.2016.168.htmlen
dc.rightsArchived with thanks to Nature reviews. Nephrologyen
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectKidneyen
dc.subjectrenalen
dc.subjectcanceren
dc.subjectepigeneticsen
dc.subjectmethylationen
dc.subjecthistone modificationen
dc.subjectmicro RNAen
dc.titleThe epigenetic landscape of renal cancer.en
dc.typeArticleen
dc.identifier.journalNature reviews. Nephrologyen
dc.date.accepted2016-11-
rioxxterms.funderInternalen
rioxxterms.identifier.projectUoW191216MMen
rioxxterms.versionAMen
rioxxterms.licenseref.urihttps://creativecommons.org/CC BY-NC-ND 4.0en
rioxxterms.licenseref.startdate2017-07-01en

Related articles on PubMed

This item is licensed under a Creative Commons License
Creative Commons
All Items in WIRE are protected by copyright, with all rights reserved, unless otherwise indicated.